Chem-/Biotech

Better adjuvants

RiboxX GmbH

RiboxX GmbH is a spin-off from the TU Dresden and has a patented platform technology for the production of double-stranded RNA. This enables the development and production of novel adjuvants for vaccines and immunotherapeutics, which RiboxX is collaborating with various companies worldwide to test. The materials can be manufactured according to GMP guidelines for use in clinical trials.

TGFS has been a shareholder in the company since 2009.